chronic kidney disease, renal failure treatment, kidney disease treatment, bioova, regenerative medicine, chronic kidney disease treatment,BioOva Chronic Kidney Disease Treatment: Chronic Kidney Disease (CKD), also called chronic kidney failure, describes the gradual loss of kidney function. Your kidneys filter wastes and excess fluids from your blood, which are then excreted in your urine. When chronic kidney disease reaches an advanced stage, dangerous levels of fluid, electrolytes and wastes can build up in your body.  BioOva regenerative medicine is an effective renal failure treatment.

In the early stages of chronic kidney disease, you may have few signs or symptoms. Chronic kidney disease may not become apparent until your kidney function is significantly impaired.

Treatment for chronic kidney disease focuses on slowing the progression of the kidney damage, usually by controlling the underlying cause. Chronic kidney disease can progress to end-stage kidney failure, which is fatal without artificial filtering (dialysis) or a kidney transplant.

Renal Failure Treatment : BioOva Regenerative Medicine

Chronic Kidney Disease Treatment Results

 BioOva Regenerative Medicine Chronic Kidney Disease Treatment: The patient with high plasma creatinine levels was recommended to start dialysis as renal failure treatment. The patient rejected this option from his Kidney Disease doctor and opted to use BioOva regenerative medicine.

The patient received 45 x IM injections of 1 ml BioOva regenerative medicine at a concentration of 10 mg/ml alternate days. Kidney function was assessed by measuring creatinine, electrolyte and protein levels in blood and urine samples followed by ultrasound imaging of both kidneys and determination of  size of both kidneys and thickness of parenchymal layers.

BioOva is another treatment option for chronic kidney disease treatment.

 

We started intramuscular administration of 5 mg/ml bioOva to polycystic kidney disease patient on July 4, 2015 which lasted through September 22, 2015. Results indicate that plasma creatinine levels which represents most important indicator of kidney function after 2 mo and 18 days of treatment diminished from 438 µMol/L to 318 µMol/L which represents 13.2% drop.   In the order to reveal a possible long lasting effect of BioOva Regenerative Medicine we stopped treatment for the period of 23 days. As a result plasma creatinine value went a little  up from low 318 µMol/L  to high 380 µMol/L   and for the period of  22 day stayed practically unchanged (376 µMol/L) with subsequent drop in 15 days to 350 µMol/L  in which range it fluctuated  for the rest seven  months of observation. (Fig, 1) This data indicates that BioOva may serve as a prospective alternative and all natural treatment for CKD patients.

chronic kidney disease treatment, renal failure treatment, regenerative medicine, bioova,
Fig. 1 Drop in blood serum creatinine levels in polycystic chronic kidney disease patient after intramuscular administration of 1 ml of 5 mg/ml of bioOva (45x1ml injections administered each other day)

 

 

For example, from July 4, 2015 when bioOva treatment started, till its completion by September 22, 2015 protein concentration in urine samples decreased from 3.20g/L to 1.71 g/L which represents 46.6 % reduction.

chronic kidney disease treatment, renal failure treatment, regenerative medicine, bioova,
Fig. 2 Drop in concentration of total protein in urine of polycystic chronic kidney disease patient after intramuscular administration of 1 ml of 5 mg/ml of BioOva (45x1ml injections administered each other day)

 

 

 

 

We observed a decrease in total protein concentration in urine of same patient which may indicate  improvement in glomeruli function reducing leakage  of proteins through  filters of  the kidney. (Fig.2).      

 

 

 

According ultrasound examination report dated June 8, 2015 before treatment dimensions of right kidney were 94×41×43 mm, with clear contours and irregular on the external surface. The cyst of up to 13 mm was detected on the level of the upper segment, the cyst of up to 16 mm was detected on the level of the lower edge, and the cyst of up to 16 mm was detected on the posterior surface on the level of the middle third.  Corticomedullary differentiation of parenchyma was preserved. Thickness of parenchyma was up to 17 mm on the level of middle segment. Main pattern of blood flow was decreased (Fig.3) .   

 
chronic kidney disease treatment, renal failure treatment, bioova regenerative medicine,
Fig.3 Ultrasonograms of right (a), left (b) kidneys and their corresponding parenchymal layers (c) of CKD patient before BioOva treatment started (June 8, 2015).

Dimensions of left kidney were 70×42×41 mm. Contours were clear, irregular on the upper edge, where the cyst of up to 42 mm was detected in upper segment; the cyst of up to 25 mm was detected on the external edge on the level of the middle segment. The cyst of up to 17 mm was detected on the lower edge; the cyst of up to 14 mm was detected on the posterior edge on the level of the middle segment. Corticomedullary differentiation of parenchyma was preserved. Thickness of parenchyma was up to 13 mm on the level of middle segment. Sinus echogenicity was not increased.

Ultrasonograms obtained after completion of BioOva treatment  dated Dec 4, 2015 showed

 the following: dimensions of right kidney were 98×45×40mm contours of the right kidney were not smooth; one cyst with dimensions of 2.05 cm was found in the lower segment. Pelvicalyceal system was not dilated. Thickness of parenchyma was within normal range (16.9 mm). No concretions are found. Parenchyma was unchanged; corticomedullary differentiation was observed. Adrenal gland was not visualized and no mass lesions in its plane was observed.  (Fig.4)

renal failure treatment, chronic kidney disease treatment, bioova, regenerative medicine
Fig.4 Ultrasonograms of right (a), left (b) kidneys and their corresponding parenchymal layers (c) of CKD patient after completion of BioOva treatment (December 4, 2015)

Dimensions of left kidney were 76×41×43  Contours of the left kidney were not smooth; cysts with dimensions of 5.08 cm and 3.54 cm were found in the upper segment, and a cyst with dimensions of 2.44 cm was found in the lower segment. Pelvicalyceal system was not dilated. Thickness of parenchyma was within normal range  (1.62 cm). No concretions were found. Parenchyma was unchanged; corticomedullary differentiation was observed. Adrenal gland was not visualized; no mass lesions in its plane were observed.

Renal failure treatment, chronic kidney disease treatment, regenerative medicine,
Fig.5 Summary of ultrasonogram results for CKD patient before and after bioOva treatment

Summary of ultrasonogram demonstrates that BioOva regenerative medicine treatment of  Chronic Kidney Disease patients, aside improvement in creatinine and protein readings, also results in several positive changes in renal volumetry. For example, volumes of both right and left kidneys by the end of therapy increased by 6.8% and 33.5% accordingly. Especially it is notable for left kidney, which before BioOva therapy suffered a substatianal loss of its anatomical size.

It is also being observed that thickness of renal parenchymal layer in left kidney normalized thickening from 13 mm to normal 16.2 mm , while in right kidney both parameters stayed practically unchanged. Positive changes  in size and thickness of left kidney without notable changes  of same  parameters of left kidney may indicate, that BioOva extract has ability to act selectively by targeting  problematic areas only.

Ultrasonogram investigation before treatment revealed presence of multiple cysts of different sizes in both kidneys.  After BioOva therapy number of cysts in both kidneys was reduced from 3 to 1 in right kidney and from 4 to 3 in left kidney. On the other hand, ultrasonogram images showed that some cysts became bigger especially in left kidney which possibly occurred  due to dramatic expansion of renal volume in left kidney which might stretch the cysts to  bigger diameter detected by imaging device.

Fields marked with an * are required